{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-133766","form_type":"8-K","ticker":"MCRB","cik":"0001609809","company_name":"Seres Therapeutics, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.243301+00:00","generated_at":"2026-06-02T10:22:02.033031+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Seres Q1 net loss $40.1M, VOWST sales $10.1M; SER-155 data expected Q3","bullets":["Net loss $40.1M vs $71.2M YoY; VOWST net sales $10.1M (642 units).","Received ~1,411 VOWST enrollment forms, ~1,083 new patient starts in Q1.","SER-155 Phase 1b Cohort 2 data readout expected end of Q3 2024.","Cash $111.2M; expects runway into Q4 2024; may draw $45M debt tranche or use ATM.","Marella Thorell appointed EVP and CFO following David Arkowitz's retirement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-133766","json":"https://secwatch.observer/filing/0001193125-24-133766.json","markdown":"https://secwatch.observer/filing/0001193125-24-133766.md","text":"https://secwatch.observer/filing/0001193125-24-133766.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1609809/000119312524133766/0001193125-24-133766-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1609809/000119312524133766/d812139d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T10:22:02.033031+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"279c02aec7293ae19b0bf47b1e254b8a8529bace","claim":"Seres Therapeutics, Inc. reported first quarter 2024 results: revenue $10.1 million, net income $40.1 million.","evidence_excerpt":"BUSINESS UPDATES Continued market adoption of VOWST ® with approximately 1,411 patient enrollment forms received, approximately 1,083 new patient starts, and net sales of $10.1 million during Q1 2024, and accelerated net sales in March and April SER-155 Phase 1b placebo-controlled Cohort 2 clinical readout expected end of Q3 2024 Further microbiome therapeutic","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312524133766/0001193125-24-133766-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2024"},{"label":"Revenue","value":"$10.1 million"},{"label":"Net income","value":"$40.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}